Analyst
Jeffries
Equibles does not estimate personal net worth.
Dennis Ding is recorded as Analyst at Jeffries. Dennis Ding has spoken on 3 earnings calls across 3 companies, most recently for Ani Pharmaceuticals Inc on May 8, 2026. Those appearances were for Ani Pharmaceuticals Inc (ANIP), Crinetics Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (INDV). The companies whose calls Dennis Ding spoke on are classified in the Healthcare sector.
“So, you know, on the Q2 soft guidance, it seems to imply $117 to $128 million for criptropin at the midpoint. Maybe talk about the pushes and pulls on that number and what's driving your confidence today in achieving that, and how much visibility do you have on orders over the next 45 days?”
“And if I can have a follow-up for your preclinical oral TSHR antagonist, how do you think about this approach going after the receptor versus going after the autoantibodies?”
“So if I can ask on Lily's Bernipatide, I mean, they sound fairly excited about it and its potential in substance use disorders, and they started Phase II in OUD on a background of buprenorphine, which I'm assuming is Suboxone.”
Jeffries
Analyst
Transcript header (unverified)
Drug Manufacturers - Specialty & Generic · Healthcare
Crinetics Pharmaceuticals, Inc.
Biotechnology · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
Crinetics Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Crinetics Pharmaceuticals, Inc.
